Biond Biologics, GIBF Close $8M Investment and Collaboration

Created at 1 Jun · 11:17 UTC1 source↑ Market-relevant

IN SHORT

Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) have announced the closing of an $8 million investment and collaboration. The partnership aims to advance oncology programs in China.

Key Numbers

$8 millioninvestment amount

Who's Involved

Biond Biologics Ltd.

private clinical-stage company

Guangzhou-Israel Biotechnology Fund (GIBF)

investment fund

Key facts

Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) closed an $8 million investment.
The companies will collaborate to advance oncology programs.
The collaboration focuses on programs in China.

This investment and collaboration between Biond Biologics and GIBF signifies a strategic move to leverage Biond's oncology programs within the Chinese market. GIBF's involvement suggests a focus on bridging international biotechnology innovation with Chinese market opportunities.

↳ Why This Matters

What Happens Next

01Advancement of first-in-class oncology programs in China.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

Biond Biologics, GIBF Close $8M Investment and Collaboration

PiQ Daily

Key facts

Get the newsletter.

Biond Biologics, GIBF Close $8M Investment and Collaboration

PiQ Daily

Key facts

Get the newsletter.